Welcome to LookChem.com Sign In|Join Free
  • or
1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-[(1R)-1-hydroxy-2-methylpropyl]-9-(phenylmethyl)-, (3R)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

461019-79-4

Post Buying Request

461019-79-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

461019-79-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 461019-79-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,6,1,0,1 and 9 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 461019-79:
(8*4)+(7*6)+(6*1)+(5*0)+(4*1)+(3*9)+(2*7)+(1*9)=134
134 % 10 = 4
So 461019-79-4 is a valid CAS Registry Number.

461019-79-4Downstream Products

461019-79-4Relevant academic research and scientific papers

Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite

Nishizawa, Rena,Nishiyama, Toshihiko,Hisaichi, Katsuya,Matsunaga, Naoki,Minamoto, Chiaki,Habashita, Hiromu,Takaoka, Yoshikazu,Toda, Masaaki,Shibayama, Shiro,Tada, Hideaki,Sagawa, Kenji,Fukushima, Daikichi,Maeda, Kenji,Mitsuya, Hiroaki

, p. 727 - 731 (2007)

Hydroxylated derivatives were designed and synthesized based on the information of oxidative metabolites. Compounds derived from β-substituted (2R,3R)-2-amino-3-hydroxypropionic acid showed improved inhibitory activities against the binding of MIP-1α to h

Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5- dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Nishizawa, Rena,Nishiyama, Toshihiko,Hisaichi, Katsuya,Minamoto, Chiaki,Murota, Masayuki,Takaoka, Yoshikazu,Nakai, Hisao,Tada, Hideaki,Sagawa, Kenji,Shibayama, Shiro,Fukushima, Daikichi,Maeda, Kenji,Mitsuya, Hiroaki

, p. 4028 - 4042 (2011/08/21)

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented.

DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT

-

Page 288-289, (2010/02/05)

A pharmaceutical composition for prevention and/or treatment for HIV infection or AIDS induced by the infection which comprises, as an active ingredient, a triazaspiro[5.5]undecane derivative, a quaternary ammonium salt thereof, an N-oxide thereof, or a n

TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

-

Page 31-32, (2010/02/05)

Triazaspiro[5.5]undecane derivatives of the formula (I), quaternary ammonium salts thereof, N-oxides thereof, non-toxic salts thereof, or pharmaceutical compositions comprising them, as active ingredients (wherein R1 is formula (II) or formula

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 461019-79-4